

**ATTORNEY DOCKET NO. 14014.0346U1
PATENT****IN THE CLAIMS**

Please cancel claims 11, 22, 24 and 28 without prejudice

Please amend claims 1, 4, 12, 15, 23, 27, 31-34 and 36 as follows:

- A²
1. (currently amended) ~~A~~ An isolated population of insulin-producing cells made by a process comprising contacting, for at least twenty-four hours, non-insulin producing cells with a growth factor selected from the group consisting of GLP-1, growth factors having amino acid sequences substantially homologous to GLP-1, and fragments thereof.
 2. (original) The population of claim 1, wherein the non-insulin producing cells are contacted with the growth factor *in vitro*.
 3. (original) The population of claim 1, wherein the non-insulin producing cells are contacted with the growth factor *in vivo*.
 4. (currently amended) The population of claim 1, wherein the non-insulin producing cells comprise ~~non-islet cells~~ cells that are not pancreatic beta cells.
 5. (original) The population of claim 1, wherein the non-insulin producing cells comprise pancreatic cells.
 6. (original) The population of claim 1, wherein the non-insulin producing cells comprise pancreatic acinar cells.
 7. (original) The population of claim 1, wherein the non-insulin producing cells comprise stem cells.
 8. (original) The population of claim 1, wherein the non-insulin producing cells comprise pancreatic stem cells.

**ATTORNEY DOCKET NO. 14014.0346U1
PATENT**

- A2
cont
9. (original) The population of claim 1, wherein the non-insulin producing cells are mammalian cells.
 10. (original) The population of claim 9, wherein the mammalian cells are human cells.
 11. (canceled)
 12. (currently amended) ~~A~~ An isolated population of insulin-producing cells made by a process comprising contacting, for at least twenty-four hours, noninsulin-producing cells with a growth factor selected from the group consisting of Exendin-4, growth factors having amino acid sequences substantially homologous to Exendin-4, or fragments thereof.
 13. (original) The population of claim 12, wherein the non-insulin producing cells are contacted with the growth factor *in vitro*.
 14. (original) The population of claim 12, wherein the non-insulin producing cells are contacted with the growth factor *in vivo*.
 15. (currently amended) The population of claim 12, wherein the non-insulin producing cells comprise ~~non-islet cells~~ cells that are not pancreatic beta cells.
 16. (original) The population of claim 12, wherein the non-insulin producing cells comprise pancreatic cells.
 17. (original) The population of claim 12, wherein the non-insulin producing cells comprise pancreatic acinar cells.
 18. (original) The population of claim 12, wherein the non-insulin producing cells comprise stem cells.
 19. (original) The population of claim 12, wherein the non-insulin producing cells comprise pancreatic stem cells.

ATTORNEY DOCKET NO. 14014.0346U1
PATENT

- A2
cont.
20. (original) The population of claim 12, wherein the non-insulin producing cells are mammalian cells.
 21. (original) The population of claim 20, wherein the mammalian cells are human cells.
 22. (canceled)
 23. (currently amended) A method of differentiating non-insulin producing cells into insulin producing cells, comprising contacting, for at least twenty-four hours, the non-insulin producing cells with a growth factor selected from the group consisting of GLP-1, growth factors having amino acid sequences substantially homologous to GLP-1, and fragments thereof.
 24. (canceled)
 25. (original) The method of claim 23, wherein the non-insulin producing cells are contacted with the growth factor *in vitro*.
 26. (original) The method of claim 23, wherein the non-insulin producing cells are contacted with the growth factor *in vivo*.
 27. (currently amended) A method of differentiating non-insulin producing cells into insulin producing cells, comprising contacting, for at least twenty-four hours, the non-insulin producing cells with a growth factor selected from the group consisting of Exendin-4, growth factors having amino acid sequences substantially homologous to Exendin-4, or fragments thereof.
 28. (canceled)
 29. (original) The method of claim 27, wherein the non-insulin producing cells are contacted with the growth factor *in vitro*.
 30. (original) The method of claim 27, wherein the non-insulin producing cells are contacted with the growth factor *in vivo*.

ATTORNEY DOCKET NO. 14014.0346U1
PATENT

- A2
dent
31. (currently amended) A method of enriching a population of cells for insulin-producing cells, comprising contacting for at least twenty-four hours, the population of cells with a ~~growth factor~~ GLP-1 or exendin-4, growth factors having amino acid sequences substantially homologous to GLP-1 or exendin-4, or fragments thereof, that differentiate[s] non-insulin-producing cells into insulin-producing cells.
32. (currently amended) A method of promoting pancreatic amylase producing cells to produce ~~both insulin and amylase~~, comprising contacting for at least twenty-four hours, the pancreatic amylase producing cells with a growth factor selected from the group consisting of GLP-1, growth factors having amino acid sequences substantially homologous to GLP-1, and fragments thereof.
33. (currently amended) A method of promoting pancreatic amylase producing cells to produce ~~both insulin and amylase~~, comprising contacting for at least twenty-four hours, the pancreatic amylase producing cells with a growth factor selected from the group consisting of Exendin-4, growth factors having amino acid sequences substantially homologous to Exendin-4, and fragments thereof.
34. (currently amended) A method of ~~treating diabetes~~ inducing insulin secretion in a subject ~~diagnosed with Type I diabetes~~ lacking insulin-producing cells, comprising administering to the subject a growth factor selected from the group consisting of GLP-1, growth factors having amino acid sequences substantially homologous to GLP-1, and fragments thereof by continuous infusion for at least twenty-four hours.
35. (original) The method of claims 34, wherein the growth factor differentiates non-insulin producing cells into insulin producing cells.
36. (currently amended) A method of ~~treating diabetes~~ inducing insulin secretion in a subject ~~diagnosed with Type I diabetes~~, comprising administering to the subject a growth factor selected from the group consisting of Exendin-4, growth factors having amino acid sequences substantially homologous to Exendin-4, and fragments thereof, wherein the exendin-4 contacts non-insulin-producing cells for at least twenty-four hours, and wherein the non-insulin-producing cells are differentiated into insulin-producing cells.

**ATTORNEY DOCKET NO. 14014.0346U1
PATENT**

- A2
cont.
- 37. (original) The method of claim 36, wherein the growth factor is administered by bolus at least once.
 - 38. (original) The method of claims 36, wherein the growth factor differentiates non-insulin producing cells into insulin producing cells.
 - 39. (withdrawn)
 - 40. (withdrawn)
 - 41. (withdrawn)
 - 42. (withdrawn)
 - 43. (withdrawn)
 - 44. (withdrawn)
 - 45. (withdrawn)
 - 46. (withdrawn)
 - 47. (withdrawn)
 - 48. (withdrawn)
 - 49. (withdrawn)
 - 50. (withdrawn)
 - 51. (withdrawn)
 - 52. (withdrawn)